NCT02772003 2026-04-13
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT04367675 2026-02-23
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
Abramson Cancer Center at Penn Medicine
Phase 1 Active not recruiting
NCT04015700 2026-02-09
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03502785 2025-07-10
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02172911 2021-02-21
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT02163057 2021-01-22
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT02960594 2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1 Completed
NCT02241369 2018-11-16
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
Inovio Pharmaceuticals
Phase 1 Completed
NCT02514213 2017-12-26
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Inovio Pharmaceuticals
Phase 1 Completed